Tuesday, April 14, 2015 10:12:36 AM
Helius Medical Technologies (CSE: HSM; OTCQB: HSDT) Inventors' Granted US Patent No. 14/341,141
"Non-Invasive Neuromodulation (NINM) For Rehabilitation of Brain Function"
NEWTOWN, PA / TheNewswire / April 14, 2015 - Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company") announced today that the US Patent and Trademark Office (USPTO) issued a third patent related to its Portable Neuromodulation Stimulation (PoNS(TM)) device and the associated therapeutic modality. U.S. Patent No. 14/341,141 "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function", issued on April 10, 2015, is directed to a non-invasive neuromodulation therapy that uses intraoral cutaneous stimulation in conjunction with cognitive exercise.
Cranial Nerve - Non Invasive Neuromodulation (CN-NINM) therapy is believed to facilitate the brain's ability to rehabilitate and compensate for symptoms caused by disease or trauma. The PoNS(TM) device and the CN-NINM therapy is currently being studied in the United States for the treatment of chronic balance disorders caused by mild-moderate Traumatic Brain Injury ("TBI") and in Canada for chronic balance and gait disorders caused by Multiple Sclerosis.
"Our growing patent portfolio continues to protect our vision to revolutionize the treatment of brain injury symptoms. Protecting our unique technology and therapeutic modality is fundamental for our growth as a company and our ability to properly and aggressively reshape this space," said Philippe Deschamps, Chief Executive Officer of Helius.
This USPTO issuance is the third patent Helius has received related to the PoNS(TM) device and the associated therapeutic modality. The first PoNS(TM) patent, US Patent No. 8,849,407, was issued on September 30, 2014. The second PoNS(TM) patent, US Patent No. 8,909,345 was issued on December 9, 2014. The Company also filed more than two dozen patent applications to protect the valuable technical features and ornamental design elements of the PoNS(TM) device. Helius expects to file additional patent applications to protect its technology, designs and therapeutic methods as they evolve.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology company focused on neurological wellness. The company's mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. For more information, please visit www.heliusmedical.com.
Recent HSDT News
- Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) • GlobeNewswire Inc. • 08/16/2024 09:00:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:15:30 PM
- Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/12/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:12:15 PM
- Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024 • GlobeNewswire Inc. • 08/06/2024 08:36:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/24/2024 08:16:09 PM
- Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke • GlobeNewswire Inc. • 06/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:15:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:30:11 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/31/2024 08:23:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/31/2024 08:21:53 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/30/2024 08:15:08 PM
- Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier • GlobeNewswire Inc. • 05/29/2024 01:00:00 PM
- Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts • GlobeNewswire Inc. • 05/20/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/14/2024 08:15:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:30:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:15:00 PM
- Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024 • GlobeNewswire Inc. • 05/10/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:31:03 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/08/2024 08:56:46 PM
- Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering • GlobeNewswire Inc. • 05/07/2024 02:15:00 AM
- Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®) • GlobeNewswire Inc. • 05/06/2024 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM